At Evoke Pharma, Inc. (NASDAQ: EVOK), we pride ourselves on our passion for patients. This passion, as well as our focused concentration on developing treatments for patients living with gastrointestinal diseases, is a key driver for our success. Established and led by specialty pharmaceutical executives with extensive experience in the US market, Evoke Pharma is committed to improving the lives of patients with gastrointestinal diseases.

Addressing unmet needs for gastrointestinal diseases

We recognize the significant unmet medical needs in the gastrointestinal space, particularly in diabetic gastroparesis. Characterized by slow or delayed gastric emptying, diabetic gastroparesis is a debilitating, chronic condition with significant impact on patients who suffer from symptoms such as nausea, abdominal pain, bloating, early satiety, and vomiting. Many patients do not achieve adequate relief of their diabetic gastroparesis symptoms due to erratic absorption of orally administered drugs. Over a decade ago, we discovered this significant gap in treatment that represented an urgent need for a new approach to therapy. Since then, we have worked tirelessly to change the way patients manage their diabetic gastroparesis symptoms since oral metoclopramide was approved in 1979.

Our commitment

Evoke Pharma is committed to ensuring that patients and healthcare professionals have access to our medication as well as the information, tools, and support they need during treatment.